Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 12 May 2005 |
| Genmab, Capital Increase as a result of employee warrant exercise | 11 May 2005 |
| Genmab, insiders' tradings | 11 May 2005 |
| Genmab, quarterly report Q1 | 10 May 2005 |
| Genmab, Announces 2005 First Quarter Results | 10 May 2005 |